930P - A retrospective single institution study evaluating clinical outcome and prognostic markers for endometrial and ovarian carcinosarcomas (CS)

Date 27 September 2014
Event ESMO 2014
Session Poster Display session
Topics Ovarian Cancer
Endometrial Cancer
Presenter Uzma Asghar
Citation Annals of Oncology (2014) 25 (suppl_4): iv305-iv326. 10.1093/annonc/mdu338
Authors U.S. Asghar1, G. Imseeh1, A.A. Kirkwood2, M. Widschwendter3, A. Olaitan3, N. Macdonald3, T. Mould3, M. McCormack3, A. Mitra3, J.A. Ledermann4, R. Arora5, R. Kristeleit6
  • 1Clinical Research Unit, University College London Hospital, NW1 2BU - London/GB
  • 2Cancer Research Uk & Ucl Cancer Trials Centre, University College London, NW1T 4TJ1 - London/GB
  • 3Gynae-oncology Unit, University College London Hospital, NW1 2BU - London/GB
  • 4Cancer Research Uk And Ucl Cancer Trials Centre, University College London Cancer Institute, WC1E6BT - London/GB
  • 5Pathology, University College London Hospital, NW1 2BU - London/GB
  • 6Uclh Dept. Of Oncology, UCL - University College London Cancer Institute, London/GB



To assess whether: (1) clinical outcomes for ovarian vs. endometrial CS were comparable (2) the epithelial histological subtype or presence of heterologous elements in the mesenchymal component impacted overall survival (OS) (3) a personal or family history (FHx) of cancer was associated with OS.


Women treated at University College London Hospital Gynae-oncology Unit between April 2002 – 2011 were identified using electronic records. Patient clinical data and full histological reports were collected retrospectively from the medical records.


82 patients (72 endometrial; 10 ovarian) with a median age of 67 years were identified. 22% had a prior cancer history and 3.6% had previously received abdominal/pelvic radiotherapy (RT). Median OS was 26.7 months.

Analysis for OS according to baseline characteristics

OS #events/n HR(95% CI) p-value
Original Tumour site
Endometrial Ovarian 33/72 6/10 1.0 1.33 (0.56 -3.17) 0.5
FIGO Stage I/II III/IV 10/37 22/33 1.0 3.22 (1.52, 6.82) 0.001
Epithelial type Poorly/un-differentiated Other 15/39 16/31 1.0 1.55 (0.75,3.18) 0.23
Cancer History No Yes 22/56 10/18 1.00 1.23 (0.59, 2.55) 0.58
Cancer FHx No Yes 26/56 7/15 1.00 1.08 (0.47, 2.49) 0.86

All ovarian CS patients had surgical resection (SR), 90% completed 6 cycles of postoperative carboplatin/paclitaxel chemotherapy (CT) with 20% complete responses (CR) and 40% partial responses (PR). 88% of endometrial CS patients were treated with SR, CT +/- RT. The response rates (RR) after CT were 70% CR and 9% PR. Neither the epithelial subtypes, nor the presence of a heterologous component showed statistically significant difference for OS.


Clinical outcome for ovarian (12%) vs. endometrial CS were comparable in regards to OS. FIGO stage was the only statistically significant prognostic factor. There was a trend for worse OS in CS with poorly/un- differentiated adenocarcinoma and/or absence of heterologous components although statistically not significant in this cohort. This warrants further clinical evaluation in a larger study.


All authors have declared no conflicts of interest.